Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Executive Summary

Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.

You may also be interested in...



Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs

Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx. 

Cerevel Puts Tavapadon Into Phase III for Parkinson’s

The company, launched in October 2018 with neuroscience programs spun out from Pfizer and supported by $350m from Bain, believes it has a treatment that could prove effective across the full spectrum of Parkinson’s disease.

Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab

Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel